01 9Celebrex
02 5Celecox
03 1celecox
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2019 Revenue in Millions : 719
2018 Revenue in Millions : 686
Growth (%) : 5
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 249
2019 Revenue in Millions : 454
Growth (%) : -45
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 17
2020 Revenue in Millions : 248
Growth (%) : -93
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2022 Revenue in Millions : 338
2021 Revenue in Millions : 344
Growth (%) : -2
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 331
2022 Revenue in Millions : 338
Growth (%) : -2
Main Therapeutic Indication : Anti-Inflammatory
Currency : USD
2018 Revenue in Millions : 443
2017 Revenue in Millions : 436
Growth (%) : 2%
Main Therapeutic Indication : Anti-Inflammatory
Currency : USD
2016 Revenue in Millions : 428
2015 Revenue in Millions : 418
Growth (%) : 3
Main Therapeutic Indication : Anti-inflammatory
Currency : USD
2017 Revenue in Millions : 465
2016 Revenue in Millions : 457
Growth (%) : 2
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 460
2018 Revenue in Millions : 458
Growth (%) : 1
Upjohn (9 months)
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2020 Revenue in Millions : 428
2019 Revenue in Millions : 526
Growth (%) : -19
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
LOOKING FOR A SUPPLIER?